Values First Advisors Inc. Makes New Investment in Inari Medical, Inc. (NASDAQ:NARI)

Values First Advisors Inc. purchased a new stake in shares of Inari Medical, Inc. (NASDAQ:NARI) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 3,116 shares of the company’s stock, valued at approximately $128,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in NARI. Bessemer Group Inc. lifted its holdings in Inari Medical by 16.4% during the first quarter. Bessemer Group Inc. now owns 2,439 shares of the company’s stock worth $117,000 after buying an additional 344 shares during the period. Wealth Enhancement Advisory Services LLC grew its stake in Inari Medical by 7.7% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 4,852 shares of the company’s stock valued at $234,000 after purchasing an additional 348 shares during the last quarter. Arizona State Retirement System increased its holdings in shares of Inari Medical by 2.5% in the second quarter. Arizona State Retirement System now owns 14,602 shares of the company’s stock valued at $703,000 after purchasing an additional 358 shares during the period. Covestor Ltd raised its stake in shares of Inari Medical by 30.2% in the first quarter. Covestor Ltd now owns 1,619 shares of the company’s stock worth $78,000 after purchasing an additional 376 shares during the last quarter. Finally, Nisa Investment Advisors LLC lifted its holdings in shares of Inari Medical by 83.5% during the second quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock worth $46,000 after purchasing an additional 435 shares during the period. 90.98% of the stock is currently owned by institutional investors.

Insider Activity at Inari Medical

In other Inari Medical news, Director William Hoffman sold 40,000 shares of the business’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $45.83, for a total transaction of $1,833,200.00. Following the transaction, the director now owns 643,296 shares of the company’s stock, valued at approximately $29,482,255.68. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Inari Medical news, CFO Mitch C. Hill sold 5,000 shares of Inari Medical stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $47.99, for a total transaction of $239,950.00. Following the transaction, the chief financial officer now directly owns 179,600 shares of the company’s stock, valued at $8,619,004. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William Hoffman sold 40,000 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $45.83, for a total transaction of $1,833,200.00. Following the completion of the sale, the director now directly owns 643,296 shares of the company’s stock, valued at approximately $29,482,255.68. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 88,000 shares of company stock valued at $4,009,340. 10.60% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research firms have issued reports on NARI. Truist Financial reduced their price target on shares of Inari Medical from $55.00 to $46.00 and set a “hold” rating for the company in a research report on Monday, October 14th. Wells Fargo & Company decreased their price objective on Inari Medical from $84.00 to $65.00 and set an “overweight” rating for the company in a report on Wednesday, July 31st. Deutsche Bank Aktiengesellschaft assumed coverage on Inari Medical in a report on Friday, August 9th. They set a “buy” rating and a $68.00 target price on the stock. Robert W. Baird decreased their price target on Inari Medical from $65.00 to $63.00 and set an “outperform” rating for the company in a report on Wednesday, July 31st. Finally, Stifel Nicolaus assumed coverage on shares of Inari Medical in a research note on Tuesday, September 17th. They set a “hold” rating and a $50.00 price objective on the stock. Six analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, Inari Medical has a consensus rating of “Hold” and an average price target of $57.44.

Inari Medical Stock Down 0.6 %

Shares of NARI opened at $43.70 on Friday. Inari Medical, Inc. has a 52-week low of $36.73 and a 52-week high of $67.13. The stock has a market cap of $2.54 billion, a PE ratio of -106.59 and a beta of 1.00. The firm’s fifty day moving average is $43.65 and its two-hundred day moving average is $45.86.

Inari Medical (NASDAQ:NARI) last posted its quarterly earnings results on Tuesday, July 30th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.25). The business had revenue of $145.82 million for the quarter, compared to analyst estimates of $143.96 million. Inari Medical had a negative return on equity of 7.51% and a negative net margin of 10.42%. As a group, research analysts anticipate that Inari Medical, Inc. will post -0.75 earnings per share for the current year.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.